Table of Contents  

Yap: Classical homocystinuria: newborn screening with early treatment effectively prevents complications


Classical homocystinuria (HCU; McKusick 236200) was first described in 1962 simultaneously by Carson and colleagues in Northern Ireland1 and Gerritsen and colleagues in Wisconsin, USA.2 Within 2 years of the condition being described, Mudd and colleagues demonstrated a deficiency of hepatic cystathionine β-synthase (CβS; EC, a pyridoxine-dependent enzyme in the methionine trans-sulphuration pathway.3 This recessively inherited condition4 is the second most treatable aminoacidopathy after phenylketonuria (McKusick 261600).

Homocysteine lies at a very important metabolic branch point between the trans-sulphuration and remethylation pathways of methionine metabolism. Cofactors involved in the metabolism of methionine include pyridoxine (vitamin B6), vitamin B12 and folate. CβS deficiency is characterized by homocystine in the urine, homocystinuria, and biochemically by severe hyperhomocysteinaemia, hypermethioninaemia and hypocysteinaemia (Figure 1). Approximately 50% of patients worldwide are biochemically responsive to pharmacological doses of pyridoxine.5


Trans-sulphuration and remethylation pathway of the methionine cycle. Yap S. Homocystinuria due to cysthathionine β-synthase deficiency. Orphanet encyclopaedia. February 2005. URL: (accessed 30 October 2012). Reproduced with permission from Professor Odile Kremp.


Homocystinuria, as we now know, may be caused by CβS deficiency and a variety of very rare other genetic problems that interfere with tetrahydrofolate-dependent or methylcobalamin-dependent conversion of homocysteine to methionine. Therefore, the use of the term ‘homocystinuria’ must be appropriately qualified by the genotypic cause of it. Classical HCU has been historically used to describe CβS deficiency and, for the purpose of this article, HCU is used synonymously with CβS deficiency.

The purpose of this review is to briefly outline the general background to CβS deficiency and the modalities of treatment available for severe hyperhomocysteinaemia in patients with CβS deficiency, to ascertain the biochemical control achieved and to comprehensively review the effects of homocysteine-lowering therapy on the long-term clinical outcome based on published long-term data in an Irish cohort of newborn screened HCU patients.


The worldwide prevalence has been reported at 1 in 344 0006 compared with a much higher incidence in Ireland of 1 in 65 000.7 This prevalence based on newborn screening and clinical ascertainment has been underdetermined due to undetected cases,8 consisting mainly of pyridoxine-non-responsive patients.

Recent reports from several Western countries, based on molecular analysis of CβS mutations, suggest a much higher incidence at about 1 in 6500–20 000.912 Studies from the Saudi Arabian countries, particularly in Qatar where there is a high rate of consanguinity (80%),13,14 show that the incidence is highest there, at 1 in 1800, based on molecular and biochemical screening.15

Homocysteine nomenclature

Du Vignead first coined the terms ‘homocysteine’ and ‘homocystine’ in 1932 to represent the sulphydryl (reduced) and the disulphide (oxidized) forms of the next-higher homologues of cysteine and cystine16 (Figure 2).17 Since then, homocysteine nomenclature has been confusing rather than helpful. Mudd and Levy6 pointed out that it was crucial for all workers concerned with homocysteine to be familiar with the long-established nomenclature so as to avoid obscuring or confusing it.


Structural forms of homocysteine found in human plasma: homocysteine, cysteine, homocysteine and homocysteine–cysteine mixed disulphide.17


A consensus statement on homocysteine terminology was published by Mudd and colleagues in 2000.18 In healthy subjects, 80–90% of homocysteine exists protein bound. The remaining free or non-protein-bound fraction (10–20%) consists of homocysteine–cysteine mixed disulphide and homocystine (Hcy–Hcy), the disulphide. The total free (non-protein-bound) homocysteine is taken as twice homocystine plus homocysteine–cysteine mixed disulphide. In vivo, only < 2% exists as the reduced form, homocysteine. Together, all these moieties make up what is called total homocysteine (tHcy).18

Genetics of cystathionine β-synthase deficiency

In 1984, the human CβS gene was mapped onto chromosome 21,19 and by in situ hybridization in 1988 it was specifically assigned to chromosome 21q22.3.20 The human complementary deoxyribonucleic acid (cDNA) for CβS was cloned and fully sequenced in 1993, with its transcribed sequence broken up into 18 exons and 17 introns.21

There are currently more than 150 known disease-causing point mutations or short deletions or insertions.22 The two most common mutations responsible for the homocystinuria phenotype include c.919G>A (p.G307S), also known as the ‘Celtic’ mutation, which heralds the more severe pyridoxinenon-responsive phenotype and is the major mutation in patients with Irish ancestry.23 The other mutation, c.833T>C (p.1278T), is associated with pyridoxine responsiveness and is a pan-ethnic mutation detected in the majority of European populations.24,25,26

Among the Qatari tribes M and K with HCU, c.1006C>T (p.R336C) is the only CβS mutation found, thus illustrating a strong founder effect causing a high prevalence of an autosomal recessive disease in a highly consanguineous population.14

Natural history

Individuals with HCU are clinically normal at birth. If untreated, HCU is accompanied by an abundance and variety of clinical and devastating pathological abnormalities manifesting in four organ systems: eyes, skeleton, vascular and central nervous systems. The clinical picture is extremely heterogeneous, ranging from patients presenting with all of the complications to individuals with no overt clinical involvement.

In 1985, Mudd et al.5 carried out a landmark study documenting the natural history of 629 HCU patients due to CβS deficiency. The data obtained resulted in time-to-event graphs for each of the major recognized complications, namely ectopia lentis, radiographical osteoporosis, clinically detected thromboembolic events and mental retardation. Of the untreated pyridoxine non-responsive patients, these time-to-event graphs predicted that:

  • 82% will have ectopia lentis by the age of 10 years

  • 27% will have had a clinically detected thromboembolic event by the age of 15 years

  • 64% will have radiological evidence of spinal osteoporosis by the age of 15 years and

  • 23% will not survive to the age of 30 years.

These well-recognized time-to-event graphs for the first time provided the clinician with a prognostic probability for the development of each stated complications when a patient remains untreated. More importantly, the result of this landmark study also establishes baselines for future evaluation of the effects of treatment in this disease.


The cardinal biochemical features of HCU are:

  1. markedly increased concentrations of plasma homocysteine (>  100 μmol/l) and methionine with a low cysteine concentration and

  2. increased concentration of urine homocystine.

The diagnosis can be confirmed by measuring CβS enzyme activity in cultured skin fibroblasts.27 Residual CβS activity in cultured fibroblasts of affected individuals has ranged from none detected up to 10% of mean control activity. There is no correlation between the amount of residual enzyme activity and clinical pyridoxine responsiveness. In addition, in vitro response to pyridoxine of the isolated enzyme does not always correlate with an in vivo response.26 Therefore, it is recommended that all patients diagnosed with HCU must have a pyridoxine trial to ascertain clinical pyridoxine responsiveness before the actual commencement of homocysteine-lowering therapy.

Molecular CβS gene testing is now readily available. The sensitivity of the methodology used should be known and it is important to differentiate between mutation scanning, mutation screening and direct sequencing of the CβS gene when interpreting molecular reports.


Clinical aims of treatment

The clinical aims of treatment in HCU depend on the age at diagnosis. If CβS deficiency is diagnosed in the newborn infant through newborn screening, as ideally it should be, the aim must be to prevent the development of ocular, skeletal, intravascular and thromboembolic complications and to ensure the development of normal intelligence. On the other hand, if the diagnosis is made late when some recognized complications have already occurred, then the clinician's goal must be to prevent life-endangering thromboembolic events and to prevent further escalation of the complications already suffered.28

To achieve these clinical aims in treatment, one must try to control, and if possible normalize, the severe hyperhomocysteinaemia that is characteristic of this condition.28

Modalities of treatment

There are currently three recognized modalities of treatment for CβS deficiency:

  1. pyridoxine (vitamin B6), in combination with folic acid and/or vitamin B12

  2. methionine-restricted, cysteine-supplemented diet and

  3. betaine.

For those who are vitamin responsive, pharmacological doses of pyridoxine in combination with folic acid and/or vitamin B12 is the treatment of choice.31,32 For vitamin non-responders, the treatment is with a methionine-restricted, cysteine-supplemented diet.3134 Pyridoxine, folic acid and vitamin B12 have been continued in pyridoxine non-responders as cofactors of methionine metabolism. More recently, betaine, a methyl donor that remethylates homocysteine to methionine, has been used as an adjunct to treatment.35

Pyridoxine trial – ascertainment for clinical pyridoxine responsiveness

When the diagnosis is confirmed with the findings of hyperhomocysteinaemia, hypermethioninaemia and hypocystinaemia, the newborn is admitted for treatment and stabilization. Pyridoxine 50 mg t.i.d. is prescribed to assess vitamin responsiveness with deproteinized amino acids monitoring every 3 days initially until stabilized.29 Biochemically, vitamin responsiveness is indicated by falling homocysteine and methionine levels while remaining on pyridoxine, in the presence of adequate vitamin B12 and folate. While on pyridoxine treatment, the newborn is deemed vitamin responsive when the free homocystine is < 5 μmol/l. However, if the free homocystine and methionine remains persistently elevated or rises while on pyridoxine, the newborn is biochemically pyridoxine non-responsive and is commenced on a methionine-restricted diet.

The status of vitamin responsiveness in a neonate may be difficult to determine on biochemistry alone. While on a trial of pyridoxine, falling homocysteine and methionine levels due to coincidental growth spurt may be mistakenly attributed to vitamin responsiveness.

The dose of pyridoxine used for a newly diagnosed adult patient is 200 mg t.i.d. It is prudent to point out that adequate response to pyridoxine may be masked in the presence of inadequate folate and vitamin B12.30


The pyridoxine dose required to achieve successful biochemical control is titrated against plasma homocysteine levels. The optimal dose is reached when, at a minimum dose of pyridoxine, the plasma homocysteine is at its lowest. Doses of pyridoxine required for a response vary markedly among pyridoxine responders. Barber and Spaeth36 achieved responses to doses of 250–500 mg/day, whereas Gaull et al.37 utilized 800–1200 mg/day of pyridoxine for a similar response. Pyridoxine 500–1000 mg/day should be given for several weeks before a patient is considered unresponsive.38

For neonates diagnosed by newborn screening, the Irish group used a dose of 150 mg/day in three divided doses of pyridoxine and a dose of 100–800 mg/day for adult patients.29 The Dutch group used dosages of 200–500 mg/day of pyridoxine in children and for adults a dose of 750 mg/day.39 The Australian group used a lower dose of 200 mg/day pyridoxine.31

Clinicians have always been mindful of patient safety in the usage of these megadoses of pyridoxine. Vitamin B6 at doses from 200 mg to 6 g has sporadically been considered as a cause of sensory neuropathy.40,41 Remarkably, these side effects have never been observed in patients with homocystinuria who received long-term treatment (up to 24 years) with dosages up to 750 mg.42,43 This is in line with the experience of the three centres, which reported a total of 1314 patient-years of pyridoxine treatment in these patients.29,31,39

A biochemical response to pyridoxine may not occur in a potentially responsive patient if folate depletion is present.44 Patients while on pyridoxine become folate depleted unless supplemented, probably as a consequence of increased flux through the remethylation pathway. The dose of folic acid generally used has been 5 mg/day in adults. Furthermore, to avoid folate refractoriness, it is mandatory to prevent deficiency of vitamin B12, the cofactor in folate-mediated remethylation of homocysteine to methionine.

For those who are responsive to pyridoxine in combination with folic acid and vitamin B12, it remains debatable whether or not long-term treatment with other measures such as methionine-restricted, cysteine-supplemented diet or betaine supplementation provide the optimal biochemical control. Even patients with maximal responsiveness to pyridoxine in the presence of adequate folate and vitamin B12 have reduced tolerance to methionine during methionine loading tests. Pyridoxine in these patients corrects only the biochemical abnormalities in the fasting state.45 Such patients, in theory, may experience abnormal episodic surges in methionine or homocysteine following protein ingestion.38 Hence, it follows that these patients may benefit from some methionine restriction or the use of small frequent feedings.45 It is good clinical practice to give general advice to these patients on reducing the intake of food containing methionine or at least distributing the methionine intake during the day.

Methionine-restricted, cysteine-supplemented diet

A methionine-restricted, cysteine-supplemented diet to correct biochemical abnormalities is used in the treatment of pyridoxine-non-responsive homocystinuria. It was initially devised by Komrower33 and Perry in 196634 and has been extensively reviewed elsewhere.32

The Irish group, which comprises predominantly pyridoxine non-responders detected through newborn screening, provides a comprehensive long-term experience on methionine-restricted, cysteine-supplemented diet.46 The dietary treatment for CβS deficiency consists of providing the components discussed in the following four sections.

Natural protein

Natural or dietary protein is given in a small amount to provide sufficient methionine, an essential amino acid, for normal growth and development. The amount given is measured in ‘exchanges’ where one exchange contains 1 g of protein (25 mg of methionine). The number of exchanges varies with time in a single patient and also between patients, as this factor is dependent on the methionine tolerance of the individual patient.46 There are increased natural protein requirements during periods of growth spurt in children and during pregnancy as the normal fetus grows, while still maintaining good biochemical control.47 Conversely, the requirement is reduced during periods of intercurrent illnesses and in conditions in which there is catabolic stress.

The aim of treatment is to maintain a plasma free homocystine of < 5 μmol/l and a methionine level of 50–70 μmol/l. In the treatment of these newborns and growing children, giving particular attention to the provision of sufficient methionine will prevent growth retardation due to a deficiency while maintaining good biochemical control.46

Synthetic protein

As the diet restricts methionine intake, it severely curtails the intake of natural or dietary protein. Hence, it is necessary to provide a synthetic protein supplement depleted of methionine in order to enable normal growth and development. This supplement is enriched with cysteine, which becomes an essential amino acid in CβS deficiency. Several of these methionine-free, cysteine-enriched amino acid mixtures are available commercially for use in patients with β deficiency. Some of these proprietary mixtures are complete with vitamins and minerals, while others are not. When using a mixture that is not complete, supplementation with vitamins and minerals mixes is necessary to prevent deficiencies.

‘Free foods’ – non-protein/methionine-containing food

‘Free foods’ are natural foods that do not contain protein or methionine, for example many vegetables and fruits. These are permitted in unlimited quantities and contribute to the caloric intake of the patient. They also provide variety in the diet.

Low-protein products

These are commercially available products that are low in protein and obtainable on prescription, for example low-protein bread, pasta, biscuits and flour. They are allowed in unlimited amounts and are considered as ‘free foods’. They play an important part in the provision of calories and variety for the patient.

The total protein intake is the sum of the natural and synthetic protein intakes. The amount of synthetic protein prescribed is inversely proportional to age and calculated per kilogram of body weight.48

Vitamins and minerals are prescribed to meet the recommended dietary allowances.49 Caloric intakes are based similar to the recommended dietary allowances.49 The provision of adequate calories to meet the energy expenditure of the patient is important in minimizing catabolism and hence hyperhomocysteinaemia.


Betaine is used in late-detected pyridoxine-non-responsive individuals for whom such a diet may be unpalatable and dietary compliance difficult to achieve.35,5054 It may be used as an adjunct to dietary restriction to obtain the best possible biochemical control.32 Anhydrous betaine is usually prescribed at 3–9 g/day in two or three divided doses in adults;31,50,53 however, the optimal dosing has not been determined.55

Additional treatment with betaine provides an alternative remethylation pathway to convert excess homocysteine to methionine, usually accompanied by a rise in plasma methionine. The resultant hypermethioninaemia has been harmless in the vast majority of cases with 226 patient-years of betaine treatment.32 However, cerebral oedema has been reported in a few cases with hypermethioninaemia > 1000 μmol/l.5658

Additional adjunct therapy

Additional medical interventions that do not affect the biochemical abnormalities but aim to reduce or eliminate the thrombotic tendencies have also been used.6 These include the avoidance of situations that predispose to an increased risk of thromboembolism and the use of high-dose antithrombotic prophylaxis with heparin or warfarin in conditions with prolonged bed rest. Aspirin, either alone or in combination with dipyridamole, has been used to normalize decreased platelet survival and minimize vascular lesions in patients with HCU.32

Therapeutic aim and biochemical control

The therapeutic aim while receiving homocysteine-lowering treatment has been reported by several centres in the past. The different centres have used different homocysteine fractions as their measurement for biochemical control. It is important to point out that, prior to 1990, measurement of total homocysteine was not possible.

The therapeutic aim for the Australian and Dutch groups was a total free homocysteine (non-protein- bound) level < 20 μmol/l, and since 1990 the Dutch group has taken a total homocysteine level < 50 μmol/l as achieving good biochemical control.31,39 The Irish group has used a target level of free homocystine < 5 μmol/l.29 The London and Manchester workers59 have used a level of free homocystine < 10 μmol/l. Together, these five centres provided a total of 2821.6 patient-years of treatment on 158 patients.60

In a newborn screened group of patients, Yap and Naughten29 defined a lifetime median of free homocystine ≤ 11 μmol/l as protective, at least up to 23.4 years, against the overt recognized complications of untreated HCU.

Long-term clinical outcome

From the ever-increasing understanding of the pathophysiology of CβS deficiency, it is known that the characteristic biochemical abnormalities are responsible for the clinical complications. Optimal treatment strategies have been aimed at reducing or normalizing these biochemical abnormalities as previously discussed. It is reasonable to assume that progressive tissue damage has occurred even prior to the appearance of any clinical signs and symptoms. Hence, maximal benefit from homocysteine-lowering therapy may only be derived from detecting the disorder in the newborn period, either by newborn screening or by high-risk screening as a result of a known family history of the disorder.26

The effectiveness of homocysteine-lowering treatment in late-detected patients has been established in several studies.5,31,39 There remains a paucity in the literature of long-term clinical outcome data on HCU patients treated from birth, as few countries screened for β deficiency. Of the increasing numbers of countries screening for HCU, the newborn screened cohort of patients remain relatively young for long-term clinical outcome assessment.

Uniquely, Ireland provides the largest cohort of newborn-screened, early treated and systematically followed up group of HCU patients with one of the longest terms of follow-up in the world.29 The following paragraph will review the long-term clinical outcome data published by Yap on the Irish HCU patients, detected through newborn screening and systematically followed up in a single centre for at least 25 years of the Irish national newborn screening programme since 1971.

The Irish group of 25 HCU patients had a total of 365.7 patient-years of treatment.29 Of the group, 21 (age range 2.5–23.4 years) were detected through newborn screening and commenced treatment within 6 weeks of birth. The remaining four (age range 16.8–20.8 years) were late detected; three were breastfed and one was a vitamin B6 responder. All except one patient were vitamin B6 non-responsive. In the 18 patients screened (mean period of follow-up 14.3 years), early dietary-treated patients who were compliant with treatment, there was no ectopia lentis, no radiological evidence of osteoporosis, no thromboembolic events and no mental handicap with age-appropriate education standards. The remaining three newborn-screened patients (age 12, 16.6, 22.8 years) who were poorly compliant with treatment developed ectopia lentis, osteoporosis and intellectual disabilities, despite the opportunity of newborn screening and an early start to treatment. This study, with 365.7 patient-years of treatment, provided the first evidence that newborn screening, early treatment and good dietary compliance, maintaining a lifetime free homocystine median of ≤ 11 μmol/l, is effective in preventing complications.29

Intellectual and neurological outcome

Intellectual disability remains the most frequent abnormality of the central nervous system and is often the first recognizable sign of CβS deficiency, presenting as developmental delay during the first and second years of life.5 It is, however, not at all a consistent finding, particularly among vitamin B6 responders. Mudd et al.5 documented a very wide range of patients’ intelligence quotients (IQs) (n = 284) from 10 to 138. Vitamin B6 non-responders (n = 115; mean IQ = 57) generally fared significantly worse than vitamin B6 responders (n = 107; mean IQ = 79). The study further documented that only 4% of vitamin B6 non-responders had an IQ ≥ 90 and, when compared with their unaffected siblings, 94% had IQs < 90 and only 6% were comparable.5

General experience with CβS-deficient patients has shown that late treatment rarely, if ever, completely reverses mental impairment,5 although treatment may lead to behavioural improvement.62 Early treatment might, on the other hand, prevent mental damage, but few reports on this exist. The study by Yap et al.63 documented a mean full-scale IQ (FIQ) of 105.8 (range 84–120) in 13 early-treated vitamin B6 non-responders with a total of 187.7 patient-years of treatment, which was significantly better than that in the late-detected or untreated vitamin B6 non-responders (Figure 3). When further compared with their unaffected sibling controls (n = 8), there was no evidence of significant differences in the psychometric parameters measured, except for a higher patient FIQ (P = 0.0397). The study further showed that late treatment is better than no treatment at all in terms of intellectual outcome and that the earlier the commencement of treatment occurs, the better the outcome.

Besides intellectual disabilities, other neurological complications as a result of untreated HCU may include seizures, psychiatric disturbances and dystonia. Few studies have concentrated on the neuropathology and imaging in CβS-deficient patients. The central pathological findings have been described as arteriosclerosis, venous and arterial thrombosis and multiple small infarcts of different ages throughout the brain.64 The corresponding magnetic resonance imaging (MRI) images of cerebral infarction are non-specific; only the young age at presentation is unusual.65 Movement disorders may result from neurochemical changes in the basal ganglia with no abnormalities on computerized tomography (CT)/MRI.66

The Irish study on MRI findings and neurological outcome showed that all newborn-screened patients with good control, vitamin B6 non-responsive HCU patients (n = 8; age > 15 years) had normal MRI of the brain and normal neurological examinations.66,67 The remaining poorly controlled newborn-screened and late-detected patients (total = 15) were found to have a combination of microinfarcts on MRI of the brain and abnormal neurology. However, none had peripheral neuropathy.66,67

Ocular outcome

Ectopia lentis is a recognized complication of untreated HCU. The natural history for untreated vitamin B6 non-responders is such that 82% will have dislocated lens by age 10 years.5 Mudd et al.5 demonstrated a two-year lag period before appreciable lens dislocation occurred. Cruysberg et al.68 emphasized the diagnostic significance of high degrees of progressive myopia at a young age, due to lens subluxation, in HCU patients. Taylor et al.69 further reported on the detrimental effect of late diagnosis on best corrected visual acuity (BCVA) in patients with HCU.

The Irish ocular outcome studies showed no ocular pathology and a vision of 20/20 bilaterally in the newborn-screened patients (n = 15; 250 patient-years of treatment) with good biochemical control. This was significantly different when compared with the late-detected group (n = 14); P < 0.0001). The poorly controlled newborn-screened patients (n = 6) were also significantly more myopic than the well-controlled newborn-screened group (P < 0.0001). This group of 40 HCU cases studied had a total of 564 patient-years of treatment.70 A further study by the Irish group demonstrated that HCU patients (n = 14; 12 newborn screened) with no ocular pathology had ocular axial lengths comparable with the normal adult eye. It also showed that homocystinuria patients with complete lens dislocation in at least one eye have significantly increased ocular axial length, and this had never been demonstrated before.71

Skeletal outcome

A variety of skeletal abnormalities have been associated with untreated HCU. Kyphoscoliosis, dolichosternomelia, pectus carinatum and genu valgum have all been described. However, osteoporosis remains the most consistent skeletal change, most commonly found in the spine followed by long bones, in untreated patients with HCU.5 The natural history of osteoporosis is such that 50% will have radiological evidence of spinal osteoporosis by age 15 years, and this further increases to 80% by age 30 years.5 Parrot et al.72 reported that spinal and femoral osteoporosis was evident by dual-energy X-ray absorptiometry (DEXA) scans in all of their six late-detected HCU patients (five vitamin B6 non-responsive), which concurs with the natural history. Deficient collagen cross-linking has been hypothesized as the pathophysiology for the development of osteoporosis in β deficiency.73 Lubec and colleagues in 1996 provided further data showing normal plasma parameters for collagen type I and type III with reduced collagen cross-linkers to support this hypothesis.74 Osteoporosis as a complication of untreated deficiency has been documented in several studies with few on the effects of treatment.

The Irish group has previously reported no radiological evidence of osteoporosis in their newborn-screened, good-control patient cohort.29 Using DEXA scans for the assessment of osteoporosis, Yap et al.47,75 studied a total of 18 HCU patients with an age range of 15.6–35 years. All the newborn-screened, well-controlled patients (n = 6) showed normal bone mineral densities. Of the remaining 12 patients, five were newborn-screened, poorly controlled patients and seven were late-detected patients; two developed osteoporosis, one from each of these groups. According to the natural history of 50% developing radiological osteoporosis by age 15 years, at least 9 of these 18 patients studied would have developed osteoporosis if they had remained untreated. Instead, only two patients had osteoporosis based on the World Health Organization (WHO) criteria for osteoporosis despite a more sensitive test (P = 0.0275).47,75

Vascular outcome

Thromboembolic events are the major cause of morbidity and mortality for untreated HCU. The vascular risk is such that half of the patients will have a vascular event before age 30 years and there is predicted to be one event per 25 years at the time of maximal risk.5 Thus, this landmark study established baselines for the evaluation of the effect of treatment and provided suggestive evidence for benefit.5

Up until the late 1990s, effects of treatment on vascular outcomes had initially been reported in single-centre studies on patients with CβS deficiency.29,31 Treatment was shown to be effective not only in patients with isolated CβS deficiency but also in those patients who carried the additional factor V Leiden, a recognized thrombotic risk factor.76 The findings were similar when patients from two additional centres were studied.28 The total number of patients studied thus far, however, remains comparatively small.

An international multicentre collaborative study was carried out to specifically document vascular outcomes and explore the effectiveness of homocysteine-lowering treatment on cardiovascular risk in patients with CβS deficiency.60 This study included 158 patients with 2821.6 patient-years of treatment from five centres: Sydney, Nijmegen, Dublin, Manchester and London. All participating centres have used re cognized treatment regimens with minor modifications.

The natural history predicts one vascular event per 25 years,5 and thus in 2821.6 patient-years of treatment at least 112 vascular events would have occurred if these patients had remained untreated. Instead, only 17 vascular events were recorded in 12 treated patients. This difference is highly significant, with a relative risk of 0.09 [95% confidence interval (CI) 0.036 to 0.228; P < 0.0001]. There was also no evidence of non-homogeneity in the vascular outcomes of each centre despite the minor differences in the treatment regimens used. The documented vascular events included pulmonary embolism, sagittal sinus thrombosis, deep-vein thrombosis, cerebrovascular accidents, abdominal aortic aneurysm, transient ischaemic attacks and myocardial infarction.60 The evidence from this multicentre study conclusively shows that chronic homocysteine-lowering treatment is effective in reducing the vascular risk in HCU patients.

Biochemical control during chronic treatment was also documented and expressed as the mean [± standard deviation (SD)] level of plasma homocysteine.60 Despite the aim of achieving normal levels, the post-treatment levels were several times higher than the mean for the corresponding normal population of each centre (Table 1). The authors concluded that this finding may have relevance to the concept of mild hyperhomocysteinaemia and its supposed associated cardiovascular risk.


Biochemicalcontrol among pyridoxine non-responders

Centres Mean (± SD) levels of homocystine during chronic treatment (μmol/l)
Free Hcy [0]a,b Total free Hcy [3.3–3.7 ± 1]a,b Total Hcy [15–19]a,b
Sydney 33 ± 17.0
Nijmegen 34 ± 13.7 88 ± 34.5
Dublin 16.7 ± 11.7 108 ± 55.0
Manchester 31.4 ± 35.9
London 33.3 ± 29.9

a Values given in square brackets are the upper limits of normal for the parameters.

b From references 17 and 60.


Undoubtedly, homocystinuria due to CβS deficiency causes an array of devastating complications when left untreated. Many studies have shown over the years that homocysteine-lowering treatment is effective in ameliorating complications and preventing the development of new complications in late-detected patients.

Half a century has passed since the first discovery of HCU in 1962. Much knowledge has been gained into the pathophysiology of this condition but clinical studies into the effectiveness of treatment still lag behind. In this last decade, Yap et al. have systematically documented clinical end points in a group of Irish newborn-screened and treated patients with pyridoxine-non-responsive HCU. The published data, which are reviewed in this paper, comprehensively documented that early homocysteine-lowering treatment is effective in preventing all the recognized complications of untreated HCU. It was shown that good clinical outcomes could be achieved without completely normalizing the homocysteine levels.

Initially thought to be generally a rare, serious and even life-threatening condition, homocystinuria has been proven by molecular studies to be more common than initially assumed. Clinical studies have now confirmed that it is indeed a very treatable inherited condition. The data from the Irish studies point favourably towards advocating newborn screening for homocystinuria, whereby the patients diagnosed, with early treatment, will have the best possible normal clinical outcome.


The author wishes to acknowledge all collaborators, patients and their parents and all the multidisciplinary teams who tirelessly care for these patients at the various centres; and Dr Godfried HJ Boers for advice and reading of the completed manuscript.

Conflict of interest




Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962; 7:505–13.


Gerritzen T, Vaughn JG, Waisman HA. The identification of homocystine in the urine. Biochem Biophys Res Commun 1962; 9:493–6.


Mudd SH, Finkelstein JD, Irreverre F, et al. Homocystinuria: an enzymatic defect. Science 1964; 143:1443–5.


Finkelstein JD, Mudd SH, Irreverre F, et al. Homocystinuria due to cystathionine synthase deficiency: the mode of inheritence. Science 1964; 146:785–7.


Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37:1–31.


Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Baeudet AL, Sly WS, Valle D (eds.) The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995. pp. 1279–1327.


Naughten ER, Yap S, Mayne PD. Newborn screening for homocystinuria: Irish and worldwide experience. Eur J Pediatr 1998; 157(Suppl. 2):S84–87.


Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. Mol Genet Metabol 2010; 99:1–3.


Gaustadnes M, Ingerslev J, Rutiger N. Prevalence of congenital homocystinuria in Denmark. N Engl J Med 1999; 340:1513.


Linnebank M, Homberger A, Junker R, et al. High prevalence of the I278T mutation of the human cystathionine beta-synthase detected by a novel screening application. Thromb Haemost 2001; 85:986–8.


Refsum H, Fredriksen A, Meyer K, et al. Birth prevalence of homocystinuria. J Pediatr 2004; 144:830–2.


Janosik M, Sokolova J, Janosikova B, et al. Birth prevalence of homocystinuria in Central Europe: frequency and pathogenicity of mutation c.1105C>T (p.R369C) in the cystathionine beta-synthase gene. J Pediatr 2009; 154:431–7.


Al-Gazali LI, Bener A, Abdulrazzaq YM, et al. Consanguineous marriages in the United Arab Emirates. J Biosoc Sci 1997; 29:491–7.


El-Said MF, Badii R, Bessisso MS, et al. A common mutation in the CBS gene explains a high incidence of homocystinuria in the Qatari population. Hum Mutat 2006; 27:719.


Zschocke J, Kebbewar M, Gan-Schreier H, et al. Molecular neonatal screening for homocystinuria in the Qatari population. Hum Mutat 2009; 30:1021–2.


Butz LW, du Vigneaud V. The formation of a homologue of cysteine by the decompensation of methionine with sulphuric acid. J Biol Chem 1932; 99:135– d42.


Yap S. Classical homocystinuria: vascular risk and its prevention. J Inherit Metab Dis 2003; 26:259–65.


Mudd SH, Finkelstein JD, Refsum H, et al. Homocysteine and its disulphide derivatives. A suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000; 20:1704–6.


Skovby F, Krassiko¡ N, Franke U. Assignment of the gene for cystathionine β-synthase to human chromosome 21 in somatic cell hybrids. Hum Genet 1984; 65:291–4.


Munke M, Kraus JP, Ohura T, et al. The gene for cystathionine β-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. Am J Hum Genet 1998; 42:550–9.


Kraus JP, Le K, Swaroop M, et al. Human cystathionine β-synthase cDNA: sequence, alternative splicing, and expression in cultured cells. Hum Mol Genet 1993; 2:1633–8.


Kraus JP, Janosick M, Kozich V, et al. Cystathionine beta synthase mutations in homocystinuria. Hum Mutat 1999; 13:362–73.〈362::AID-HUMU4〉3.0.CO;2-K


Gallagher PM, Ward P, Tan S, et al. High frequency (71%) of cystathionine beta synthase mutation G307S in Irish homocystinuria patients. Hum Mutat 1995; 6:177–80.


Kozich V, Kraus JP. Screening for mutations by expressing patient cDNA segments in E. coli: homocystinuria due to cystathionine beta synthase deficiency. Hum Mutat 1992; 1:113–23.


Kraus JP. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis 1994; 17:383–90.


Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Baeudet AL, Sly WS, et al. (eds.) The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1995. pp. 2007–54.


Fowler B, Kraus J, Packman S, Rosenberg LE. Homocystinuria. Evidence of 3 distinct classes of cystathionine β-synthase mutants in cultured fibroblasts. J Clin Invest 1978; 61:645–53.


Yap S, Naughten ER, Wilcken B, et al. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine betasynthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost 2000; 26:335–40.


Yap S, Naughten E. Homocystinuria due to cystathionine β-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inher Metab Dis 1998; 21:738–47.


Wilcken B, Turner B. Homocystinuria: reduced folate levels during pyridoxine treatment. Arch Dis Child 1973; 48:58–62.


Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria and effects of treatment. J Inherit Metab Dis 1997; 20:295–300.


Boers GHJ, Yap S, Naughten E, et al. The treatment of high homocysteine concentrations in homocystinuria. Biochemical control and their vascular outcome. In: Robinson K (ed.) Homocysteine and Vascular Disease. Kluwer Publications, 2000. pp. 387–409.


Komrower GM, Lambert AM, Cusworth DC, et al. Dietary treatment of hornocystinuria. Arch Dis Child 1966; 41:666–71.


Perry TL, Dunn HG, Hansen S, et al. Early diagnosis and treatment of homocystinuria. Pediatrics 1966: 37:502–5.


Wilcken DEL, Dudman NPB, Tyrrell PA. Homocystinuria due to cystathionine β-synthase deficiency – the effects of betaine treatment in pyridoxine-responsive patients. Metabolism 1985; 34:1115–21.


Barber CW, Spaeth GL. Pyridoxine therapy in homocystinuria. Lancet 1967; 1: 337.


Gaull GE, Rassin DK, Struman JA. Pyridoxinedependency in homocystinuria. Lancet 1968; 2: 1302.


Ubbink JB, Becker PJ, Vermaak WJ, et al. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995: 41:1033–7.


Kluijtmans LA, Boers GH, Kraus JP, et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet 1999; 65:59–67.


Parry GJ, Bredensen DE. Sensory neuropathy with low dose pyridoxine. Neurology 1985; 53:1466–8.


Schaumberg H, Kaplan J, Windebanke A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med 1983; 309:445–8.


Boers GHJ. Homocystinuria, a risk factor of premature vascular disease. Clinical Research Series no 3. Dordrecht: Foris Publications; 1986.


Mpofu C, Alani SM, Whitehouse, et al. No sensory neuropathy during pyridoxine treatment in homocystinuria. Arch Dis Child 1991; 6:1081–2.


Morrow G III, Barnes LA. Combined vitamin responsiveness in homocystinuria. J Pediatr 1972; 81:946–54.


Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31:624–8.


Yap S. Doctorate of Medicine Thesis. RCSI/NUI; 2000.


Yap S, Barry-Kinsella C, Naughten ER. Maternal pyridoxine non-responsive homocystinuria: the role of dietary treatment and anticoagulation. BJOG 2001; 108:425–8.


Francis D. Disorders of amino acid metabolism. In Diets for Sick Children, 4th edn. Oxford: Blackwell Scientific Publications; 1987.


Department of Health. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom – Report on Health and Social Subjects No. 41. London: HMSO; 1991.


Berlow S, Bachman RP, Beny GT, et al. Betaine therapy in homocystinuria. Brain Dysfunct 1989; 2:10.


Wiley VC, Dudman NPB, Wilcken DEL. Interrelations between plasma free and protein bound homocysteine and cysteine in homocystinuria. Metabolism 1988; 37:191–5.


Wiley VC, Dudman NPB, Wilcken DEL. Free and proteinbound homocysteine and cysteine in cystathionine β-synthase deficiency: Interrelations during short- and longterm changes in plasma concentrations. Metabolism 1989; 38:734–9.


Smolin LA, Benevenga J, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981; 99:467–72.


Wilcken DEL, Wilcken B, Dudman NPB, et al. Homocystinuria – the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983; 309:448–53.


Schwahn BC, Hafner D, Hohlfeld T, et al. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol 2003; 55:6–13.


Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral oedema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet 2002; 108:57–63.


Devlin AM, Hajipour L, Gholkar A, et al. Cerebral oedema associated with betaine treatment in classical homocystinuria. J Pediatr 2004; 144:545–8.


Braverman NE, Mudd SH, Barker PB, et al. Characteristic MR imaging changes in severe hypermethioninemic states. AJNR Am J Neuroradiol 2005; 26:2705–6.


Walter JH, Wraith JE, White FJ, et al. Strategies for treatment of cystathionine β-synthase deficiency: the experience of the Willink Biochemical Genetics Unit over the past 30 years. Eur J Pediatr 1998; 157(Suppl. 2):S71–6.


Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine betasynthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001; 21:2080–5.


Grobe H. Homocystinuria (cystathionine synthase deficiency). Results of treatment in late-diagnosed patients. Eur J Pediatr 1980; 135:199–203.


Yap S, Rushe H, Howard PM, et al. The intellectual abilities of early-treated individuals with pyridoxinenonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis 2001; 24:437–47.


Schoonderwaldt HC, Boers GH, Cruysberg JR, et al. Neurological manifestations of homocystinuria. Clin Neurol Neurosurg 1981; 83:153–62.


van den Berg M, van der Knaap MS, Boers GH, et al. Hyperhomocysteinaemia; with reference to its neuroradiological aspects. Neuroradiology 1995; 37:403–11.


Kempster PA, Brenton DP, Gale AN, et al. Dystonia in homocystinuria. J Neurol Neurosurg Psychiatry 1988; 51:859–62.


Yap S, Annesley D, Ryan A, et al. Identification of micro infarcts in patients with treated homocystinuria: brain MRI and neurological findings. J Inher Metab Dis 2000; 23:63.


Yap S, Annesley D, Ryan A, et al. MRI findings in patients with treated homocystinuria. Eur J Neuro 2000; 7(Suppl. 3):107.


Cruysberg JR, Boers GH, Trijbels JM, et al. Delay in diagnosis of homocystinuria: retrospective study of consecutive patients. BMJ 1996; 313:1037–40.


Taylor RH, Burke J, O'Keefe M, et al. Ophthalmic abnormalities in homocystinuria: the value of screening. Eye 1998; 12:427–30.


Mulvihill A, Yap S, O'Keefe M, et al. Ocular findings among patients with late-diagnosed or poorly controlled homocystinuria compared with a screened, well-controlled population. J AAPOS 2001; 5:311–5.


Mulvihill A, O'Keeffe M, Yap S, et al. Ocular axial length in homocystinuria patients with and without ocular changes: effects of early treatment and biochemical control. J AAPOS 2004; 8:254–8.


Parrot F, Redonnet-Vernhet I, Lacombe D, et al. Osteoporosis in late-diagnosed adult homocystinuric patients. J Inherit Metab Dis 2000; 23:338–40.


McKusick VA. Heritable Disorders of Connective Tissue, 3rd edn. St. Louis: Mosby, 1966; p. 155.


Lubec B, Fang-Kircher S, Lubec T, et al. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996; 315:159–62.


Yap S, Naughten ER, Corlett L, et al. The effects of treatment on bone mineral density (BMD) in patients with homocystinuria due to cystathionine β-synthase (CBS) deficiency. J Inher Metab Dis 1999; 22(Suppl. 1):77.


Yap S, O'Donnell KA, O'Neill C, et al. (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency. Thromb Haemost 1999; 81:502–5.

Add comment 

Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA